Business Context and Reporting Period
Alnylam Pharmaceuticals, Inc. filed this Form 8-K on January 11, 2021, to report preliminary financial results for the fourth quarter and full year ended December 31, 2020. The company focuses on RNAi therapeutics, with key products including ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran).
Key Financial Metrics
- Q4 2020 Revenue: Approximately $112 million (ONPATTRO and GIVLAARI combined).
- Full Year 2020 Revenue: Approximately $361 million (ONPATTRO and GIVLAARI combined).
- OXLUMO Revenue: Approximately $0.3 million for the period from late November 2020 through year-end.
- Liquidity: Preliminary cash, cash equivalents, and marketable securities totaled approximately $1.9 billion as of December 31, 2020.
- Profit, Margins, and Debt: The filing text does not provide clear values for net income, profit margins, or debt levels.
Material Changes and Updates
The company provided updates on commercial launches, specifically noting initial demand for OXLUMO following its approval in the U.S. and EU in late November 2020. The reported revenue figures represent preliminary data for the company's established products and the newly launched OXLUMO.
Guidance, Outlook, and Risks
Management updated cash guidance, confirming the $1.9 billion liquidity position. The company noted that preliminary selected financial results are unaudited, subject to adjustment, and provided as an approximation. Complete financial results were scheduled for announcement in February 2021. The filing explicitly states that the information is furnished and not "filed" for purposes of Section 18 of the Exchange Act, limiting liability.
Investor Verification Checklist
- Verify the final audited revenue figures for Q4 and full-year 2020 when released in February 2021.
- Confirm the exact cash, cash equivalents, and marketable securities balance in the upcoming 10-K filing.
- Review the full commercial performance and demand trajectory for OXLUMO beyond the initial $0.3 million reported.
- Check for any adjustments to the preliminary revenue numbers due to accounting finalization.